APP and Alzheimer disease: Likewise, it prevents tau hyperphosphorylation by inhibiting GSK‐3β activity and reducing tau phosphorylation levels at S396 and S404.[219] Further research concluded that xanthoceraside reduced AD symptoms in male SD rats injected with Aβ1‐42 by altering gut microbiota composition.[220] Another study analyzed the mechanisms of action of xanthoceraside in APP/PS1 transgenic mice.